Hologic

Market position

Hologic is described as a global leader in women's health and a breast imaging and mammography systems vendor. Its take-private transaction was reported to be the largest medical devices deal in almost two decades, since Boston Scientific's $27 billion purchase of Guidant Corp in 2006.

Technology

Medical devices and tests spanning diagnostics, surgery and medical imaging, including mammography and contrast-enhanced mammography, the ThinPrep Pap test for cervical cancer screening, NovaSure endometrial ablation, breast biopsy needles (Brevera), the BioZorb implantable breast device, molecular diagnostics including multiplex technology from Mobidiag and SARS-CoV-2 assays, the Breast Cancer Index test, and the Gynesonics Sonata System, an ultrasound imaging device for uterine fibroids. The company reports holding more than 4,100 patents.

Go-to-market

Direct sales representatives and dealers, an online ordering portal for consumables (iStore), medical education and training curricula, and patient-directed materials. The company has also pursued brand partnerships, becoming title sponsor of the WTA Tour and official health partner of the Women's Tennis Association in March 2022.

Healthcare professionals and providers treating women patients, including breast imaging, diagnostics and surgical settings; the company also maintains patient-facing materials and a medical education program.

Geography

Headquartered in Marlborough, Massachusetts, with a satellite office in Santa Clara, California, and operations across 36 countries. COVID-19 test manufacturing expansion covered facilities in Wisconsin, Maine and California, and the company has collaborated in Spain and acquired companies in the UK (Endomag), Germany (SOMATEX) and Finland (Mobidiag).

History

Hologic was founded in 1985. It completed the acquisition of Cytyc Corporation on October 22, 2007 in a cash-and-stock transaction valued at approximately $6.2 billion, adding the ThinPrep Pap test and NovaSure endometrial ablation technology. It acquired Gen-Probe in 2012. In late November 2013, activist investor Carl Icahn disclosed a 12.5% stake, prompting the company to adopt a poison pill and to add two Icahn-backed directors; those nominees resigned on March 3, 2016 and Icahn exited his position by May 16, 2016. Hologic bought Westford, Massachusetts-based aesthetic medicine company Cynosure for $1.65 billion in 2017, then divested it to Clayton, Dubilier & Rice for $205 million, announced November 20, 2019 and completed December 30, 2019. During the COVID-19 pandemic the company obtained FDA emergency use authorizations for SARS-CoV-2 tests in March and May 2020, collaborated with Grifols to expand testing in Spain, and won a $119 million U.S. government contract in November 2020 to expand test manufacturing. Subsequent deals included Biotheranostics ($230 million) and SOMATEX ($64 million) in January 2021, Mobidiag ($795 million, announced April 2021 and completed June 2021), Endomag ($310 million, agreed April 2024 and completed July 2024) and Gynesonics ($350 million) in 2025.

Risks & controversies

A shareholder class action filed in January 2026 sought to block the Blackstone/TPG acquisition over allegedly incomplete merger disclosures. A stop-ship order in November followed by a voluntary recall of Brevera 9 Gauge biopsy needles is expected to hurt sales for an extended period; the product line represented roughly 5% of breast health revenue in fiscal 2025. A separate class action over the BioZorb implantable breast device reached a settlement expected to be covered by insurance. Earlier, the 2017 Cynosure acquisition for $1.65 billion was divested in 2019 for $205 million, and the company faced an activist campaign by Carl Icahn beginning in 2013 that led to a poison pill and board changes.